4-4-吗啉-3-硝基苯甲醛 | 300541-91-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 4-4-吗啉-3-硝基苯甲醛
• 中文别名: 4-吗啉-3-硝基苯甲醛
• 英文名称: 4-morpholino-3-nitrobenzaldehyde
• 英文别名: 4-morpholin-4-yl-3-nitrobenzaldehyde
• CAS: 300541-91-7
• 化学式: C₁₁H₁₂N₂O₄
• mdl: MFCD00439926
• 分子量: 236.227
• InChiKey: LIHKXKQSXJAHBN-UHFFFAOYSA-N

物化性质

• 熔点：
  57-59°C
• 沸点：
  431.6±45.0 °C(Predicted)
• 密度：
  1.340±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  75.4
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090

SDS

Name:	4-Morpholino-3-nitrobenzaldehyde 95+% Material Safety Data Sheet
Synonym:
CAS:	300541-91-7

Section 1 - Chemical Product MSDS Name:4-Morpholino-3-nitrobenzaldehyde 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
300541-91-7	4-Morpholino-3-nitrobenzaldehyde	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 300541-91-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: orange
Odor: odorless - slight odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 53 - 55 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H12N2O4
Molecular Weight: 236

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 300541-91-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Morpholino-3-nitrobenzaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 300541-91-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 300541-91-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 300541-91-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-4-吗啉-3-硝基苯甲醛 、 2,4-dimethylphenyl thiosemicarbazide 以33%的产率得到4-(2,4-Dimethylphenyl)-1-(4-morpholino-3-nitrobenzylidene)thiosemicarbazide
  参考文献：
  名称：

  4-substituted-1- (arylmethylidene) thiosemicarbazide, 4-substituted-1- (arylcarbonyl) thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof

  摘要：

  本发明涉及可选取代的4-取代-1-(芳基甲基亚胺基)硫脲、4-取代-1-(芳基羰基)硫脲及其类似物，由式I和II表示：其中A1，A2，Q和R1-R3在此定义。本发明还涉及发现具有式I和II的化合物是caspase激活剂和凋亡诱导剂的发现。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导在出现异常细胞的无控制生长和扩散的各种临床情况中的细胞死亡。

  公开号：

  US20030045581A1
• 作为产物：
  描述：

  吗啉 、 4-氟-3-硝基苯甲醛 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以100%的产率得到4-4-吗啉-3-硝基苯甲醛
  参考文献：
  名称：

  4-(二乙氨基)苯甲醛支架的扩展探索对前列腺癌醛脱氢酶活性和抗增殖活性的影响

  摘要：

  醛脱氢酶 (ALDH) 在包括前列腺癌在内的各种肿瘤类型中过度表达，被认为是治疗干预的潜在靶点。4-(二乙氨基)苯甲醛 (DEAB) 已被广泛报道为 ALDH 同种型的泛抑制剂，在这里，我们报告了 40 种 DEAB 类似物在前列腺癌细胞中的合成、ALDH 同种型选择性和细胞效力；三种类似物（14、15和16 ）显示出对 ALDH1A3 的有效抑制活性，两种类似物（18和19）显示出对 ALDH3A1 的有效抑制活性。值得注意的是，16 种类似物显示出增加的细胞毒性（IC 50= 10–200 μM) 与 DEAB (>200 μM) 相比对三种不同的前列腺癌细胞系。类似物14和18对患者来源的原发性前列腺肿瘤上皮细胞比 DEAB 更有效，作为单一药物或与多西紫杉醇联合治疗。总之，我们的研究支持使用 DEAB 作为 ALDH 抑制剂，但也揭示了密切相关的类似物，具有更高的选择性和效力。

  DOI：

  10.1021/acs.jmedchem.1c01367

文献信息

• [EN] USE OF AND SOME NOVEL IMIDAZOPYRIDINES<br/>[FR] NOUVELLES IMIDAZOPYRIDINES ET LEUR UTILISATION
  申请人：ASTRAZENECA AB

  公开号：WO2004016611A1

  公开（公告）日：2004-02-26

  The use of compounds of formula (I) wherein R1, R3, R10, m and Ar are as defined in the Specification and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial is disclosed. Certain novel compounds of formula (I), together with processes for their preparation, compositions containing them and their use in therapy are also disclosed.

  公开了在制备药物用于治疗或预防抑制激酶Itk活性有益的疾病或症状中，使用式(I)中R1、R3、R10、m和Ar所定义的化合物及其药学上可接受的盐。还公开了式(I)的某些新化合物，以及它们的制备方法、含有它们的组合物和它们在治疗中的用途。
• Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors
  申请人：Thrash Thomas

  公开号：US20060004002A1

  公开（公告）日：2006-01-05

  Various thienopyrimidine-based analog compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.

  各种噻吩并嘧啶类衍生物能够选择性地抑制Src家族的酪氨酸激酶。这些化合物在治疗包括过度增殖性疾病、血液病、骨质疏松症、神经性疾病、自身免疫病、过敏/免疫性疾病或病毒感染等多种疾病中是有用的。
• Protecting-group-free amination of halogenated nitrobenzaldehyde with palladium catalyst
  作者：Jing Cao、Jun Xiang Feng、Yong Xiang Wu、Ya Ya Tuo

  DOI：10.1016/j.cclet.2010.03.028

  日期：2010.8

  "One-step" method for the synthesis of secondary aliphatic amine substituted nitrobenzaldehyde was developed. In the presence of Pd catalyst, halogenated nitrobenzaldehyde could be smoothly coupled with secondary aliphatic amine to give the target product in hexamethylphosphamide (HMPT) media without the protection of aldehyde groups. (C) 2010 Jing Cao. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  开发了一种合成α-脂肪族胺取代硝基苯甲醛的“一步法”方法。在钯催化剂存在下，卤化硝基苯甲醛可顺利与二级脂肪族胺进行偶联反应，无需对醛基进行保护，在六甲基磷酰胺（HMPT）介质中即可获得目标产物。(C) 2010 �曹静。由Elsevier B.V.代表中国化学会出版。版权所有。
• Hypophosphorous Acid Derivatives and their Therapeutical Applications
  申请人：Acher Francine

  公开号：US20090170813A1

  公开（公告）日：2009-07-02

  Hypophosphorous acid derivatives having Formula (I) wherein .M is a [C(R3,R4)]n1-C(E,COOR1,N(H,Z)) group, or an optionally substituted Ar—CH(COOR1,N(H,Z)) group, or an a, β, or a β, g-cyclic amino acid; .R 1 is H or R, R being an hydroxy or a carboxy protecting group; .Z is H or an amino protecting group R′, benzyl oxycarbonyl, benzyl or benzyl substituted; .E is H or a C1-C3 alkyl, aryl, an hydrophobic group; .R 2 is selected in the group comprising: D-CH(R 6 )—C—(R 7 ,R 8 ), (R 11 ,R 12 )CH—C(R 9 ,R 10 ), D-CH(OH), D-[C(R 13 ,R 14 )] n3 —, C[(R 15 ,R 16 ,R 17 )] n4 , D-CH 2 , (R 18 )CH═C(R 19 ), D-(M 1 ) n6 —CO, Formula (II), PO(OH) 2 —CH 2 or (PO(OH) 2 —CH 2 ), (COOH—CH 2 )—CH 2 , with -D=H, OH, OR, (CH 2 ) n2 OH, (CH 2 ) n1 OR, COOH, COOR, (CH 2 ) n2 COOH, (CH 2 ) n1 COOR, SR, S(OR), SO 2 R, NO 2 , heteroaryl, C 1 -C 3 alkyl, cycloalkyl, heterocycloalkyl, (CH 2 ) n2 -alkyl, (COOH,NH 2 )—(CH 2 ) u1 -cyclopropyl-(CH 2 ) u2 —, CO—NH-alkyl, Ar, (CH 2 ) n2 —Ar, CO—NH—Ar; —R 3 to R 19 being H, OH, OR, (CH 2 ) n2 OH, (CH 2 ) n1 OR, COOH, COOR, (CH 2 ) n2 COOH, (CH 2 ) n1 COOR, C 1 -C 3 alkyl, cycloalkyl, (CH 2 )n1-alkyl, aryl, (CH 2 )n1-aryl, halogen, CF 3 , SO 3 H, (CH 2 ) x PO 3 H 2 , with x=0, 1 or 2, B(OH) 2 , Formula (III), NO 2 , SO 2 NH 2 , SO 2 NHR; SR, S(O)R, SO 2 R, benzyl; -M 1 is an alkylene or arylene group; -n1=1, 2 or 3, n2=1, 2 or 3, n3=0, 1, 2 or 3 and n4=1, 2 or 3, n5=1, 2 or 3, n6=0 or 1, u1 and u2, identical or different=0, 1 or 2, with the proviso that Formula (I) does not represent the racemic (3R,S) and the enantiomeric form (3R) of 3 amino,3-carboxy-propyl-2′-carboxy-ethylphosphinic acid; 3 amino,3-carboxy-propyl-4′carboxy,2′carboxy-butanoylphosphinic acid; 3 amino,3-carboxy-propyl-2′carboxy-butanoylphosphinic acid; 3 amino,3-carboxy-propyl-3′amino, 3′carboxy-propylylphosphinic acid; and 3 amino,3-carboxypropyl-7′amino-2′, 7′-dicarboxyheptylphosphinic acid, said hypophosphorous acid derivatives being diasteroisomers or enantiomers. Application as drugs.

  含有Formula (I)的次磷酸衍生物，其中.M是[C(R3,R4)]n1-C(E,COOR1,N(H,Z))基团，或者是一个可选择取代的Ar—CH(COOR1,N(H,Z))基团，或者是α，β或αβ，γ-环氨基酸；.R1是H或R，R是一个羟基或羧基保护基团；.Z是H或氨基保护基团R′，苄氧羰基，苄基或苄基取代；.E是H或C1-C3烷基，芳基，疏水基团；.R2是从以下群体中选择的：D-CH(R6)—C—(R7,R8)，(R11,R12)CH—C(R9,R10)，D-CH(OH)，D-[C(R13,R14)]n3—，C[(R15,R16,R17)]n4，D-CH2，(R18)CH═C(R19)，D-(M1)n6—CO，Formula (II)，PO(OH)2—CH2或(PO(OH)2—CH2)，(COOH—CH2)—CH2，其中-D=H，OH，OR，(CH2)n2OH，(CH2)n1OR，COOH，COOR，(CH2)n2COOH，(CH2)n1COOR，SR，S(OR)，SO2R，NO2，杂环芳基，C1-C3烷基，环烷基，杂环烷基，(CH2)n2-烷基，(COOH,NH2)—(CH2)u1-环丙基-(CH2)u2—，CO—NH-烷基，Ar，(CH2)n2—Ar，CO—NH—Ar；—R3到R19为H，OH，OR，(CH2)n2OH，(CH2)n1OR，COOH，COOR，(CH2)n2COOH，(CH2)n1COOR，C1-C3烷基，环烷基，(CH2)n1-烷基，芳基，(CH2)n1-芳基，卤素，CF3，SO3H，(CH2)xPO3H2，其中x=0，1或2，B(OH)2，Formula (III)，NO2，SO2NH2，SO2NHR；SR，S(O)R，SO2R，苄基；-M1是一个烷基或芳基基团；-n1=1，2或3，n2=1，2或3，n3=0，1，2或3，n4=1，2或3，n5=1，2或3，n6=0或1，u1和u2，相同或不同=0，1或2，但Formula (I)不代表3-氨基，3-羧基-丙基-2′-羧基-乙磷酸的消旋体(3R,S)和对映体形式(3R)；3-氨基，3-羧基-丙基-4′羧基，2′羧基-丁酰磷酸；3-氨基，3-羧基-丙基-2′羧基-丁酰磷酸；3-氨基，3-羧基-丙基-3′氨基，3′羧基-丙基磷酸；和3-氨基，3-羧基丙基-7′氨基-2′，7′-二羧基庚基磷酸，所述的次磷酸衍生物为二对映异构体或对映体。用作药物的应用。
• [EN] ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DERIVES D'ANABASEINE UTILES POUR LE TRAITEMENT DE MALADIES NEURODEGENERATIVES
  申请人：MEMORY PHARM CORP

  公开号：WO2004019943A1

  公开（公告）日：2004-03-11

  The compounds of the present invention are of formula (I): wherein A, R3, R4 is as defined herein, are useful as ligands for nicotinic receptors.

  本发明的化合物的化学式为（I）：其中A、R3、R4如本文所定义，可用作尼古丁受体的配体。